ITBO970064A0 - Uso della rifaximina e delle composizioni farmaceutiche che la conteng ono nel trattamento della diarrea da criptosporidiosi. - Google Patents

Uso della rifaximina e delle composizioni farmaceutiche che la conteng ono nel trattamento della diarrea da criptosporidiosi.

Info

Publication number
ITBO970064A0
ITBO970064A0 IT97BO000064A ITBO970064A ITBO970064A0 IT BO970064 A0 ITBO970064 A0 IT BO970064A0 IT 97BO000064 A IT97BO000064 A IT 97BO000064A IT BO970064 A ITBO970064 A IT BO970064A IT BO970064 A0 ITBO970064 A0 IT BO970064A0
Authority
IT
Italy
Prior art keywords
cryptosporidiosic
rifaximin
diarrhea
contain
treatment
Prior art date
Application number
IT97BO000064A
Other languages
English (en)
Inventor
Patrizio Ferrari
Antonella Ferrieri
Pietro Caramello
Original Assignee
Alfa Wassermann Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfa Wassermann Spa filed Critical Alfa Wassermann Spa
Publication of ITBO970064A0 publication Critical patent/ITBO970064A0/it
Priority to IT97BO000064A priority Critical patent/IT1290679B1/it
Priority to DK98101081T priority patent/DK0858804T3/da
Priority to EP98101081A priority patent/EP0858804B1/en
Priority to AT98101081T priority patent/ATE218342T1/de
Priority to DE69805672T priority patent/DE69805672T2/de
Priority to PT98101081T priority patent/PT858804E/pt
Priority to HU9800115A priority patent/HU224592B1/hu
Priority to ES98101081T priority patent/ES2178048T3/es
Priority to US09/013,655 priority patent/US5886002A/en
Priority to JP02981398A priority patent/JP4848083B2/ja
Priority to KR10-1998-0004389A priority patent/KR100436243B1/ko
Priority to CN98106920A priority patent/CN1115146C/zh
Publication of ITBO970064A1 publication Critical patent/ITBO970064A1/it
Application granted granted Critical
Publication of IT1290679B1 publication Critical patent/IT1290679B1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
IT97BO000064A 1997-02-14 1997-02-14 Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi. IT1290679B1 (it)

Priority Applications (12)

Application Number Priority Date Filing Date Title
IT97BO000064A IT1290679B1 (it) 1997-02-14 1997-02-14 Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi.
HU9800115A HU224592B1 (hu) 1997-02-14 1998-01-22 Rifaximin alkalmazása kriptosporidiózis következtében fellépő hasmenés kezelésére használható gyógyszerkészítmény előállítására
EP98101081A EP0858804B1 (en) 1997-02-14 1998-01-22 Use of rifaximin as medicament for the treatment of the diarrhoea from cryptosporidiosis
AT98101081T ATE218342T1 (de) 1997-02-14 1998-01-22 Verwendung von rifaximin als medikament zur behandlung von durch cryptosporidiose verursachten diarrhoeen
DE69805672T DE69805672T2 (de) 1997-02-14 1998-01-22 Verwendung von Rifaximin als Medikament zur Behandlung von durch Cryptosporidiose verursachten Diarrhoeen
PT98101081T PT858804E (pt) 1997-02-14 1998-01-22 Utilizacao de rifaximina como medicamento para o tratamento da diarreia de crisptosporidiose
DK98101081T DK0858804T3 (da) 1997-02-14 1998-01-22 Anvendelse af rifaximin og farmaceutiske præparater indeholdende dette i behandlingen af diarré forårsaget af cryptosporidiosis
ES98101081T ES2178048T3 (es) 1997-02-14 1998-01-22 Uso de rifaximina como medicamento para el tratamiento de diarrea por criptosporidiosis.
US09/013,655 US5886002A (en) 1997-02-14 1998-01-26 Use of rifaximin and of pharmaceutical compositions containing it in the treatment of the diarrhoea from cryptosporidiosis
JP02981398A JP4848083B2 (ja) 1997-02-14 1998-02-12 リファキシミンを有効成分として含有するクリプトスポリジオーシスに起因する下痢を治療するための医薬製剤
KR10-1998-0004389A KR100436243B1 (ko) 1997-02-14 1998-02-13 크립토스포리디오시스성 설사 치료에서의 리팍시민 및 이를함유한 의약 조성물의 용도
CN98106920A CN1115146C (zh) 1997-02-14 1998-02-13 利福昔明在治疗由隐孢子虫病引起的腹泻中的用途

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT97BO000064A IT1290679B1 (it) 1997-02-14 1997-02-14 Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi.

Publications (3)

Publication Number Publication Date
ITBO970064A0 true ITBO970064A0 (it) 1997-02-14
ITBO970064A1 ITBO970064A1 (it) 1998-08-14
IT1290679B1 IT1290679B1 (it) 1998-12-10

Family

ID=11341939

Family Applications (1)

Application Number Title Priority Date Filing Date
IT97BO000064A IT1290679B1 (it) 1997-02-14 1997-02-14 Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi.

Country Status (12)

Country Link
US (1) US5886002A (it)
EP (1) EP0858804B1 (it)
JP (1) JP4848083B2 (it)
KR (1) KR100436243B1 (it)
CN (1) CN1115146C (it)
AT (1) ATE218342T1 (it)
DE (1) DE69805672T2 (it)
DK (1) DK0858804T3 (it)
ES (1) ES2178048T3 (it)
HU (1) HU224592B1 (it)
IT (1) IT1290679B1 (it)
PT (1) PT858804E (it)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
CA2523714A1 (en) * 2003-04-30 2004-11-18 The Institutes For Pharmaceutical Discovery, Llc Substituted carboxylic acids
US20060210492A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Use of rifaximin for treatment and prevention of periodontal conditions
US20060210483A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections
US8003118B2 (en) * 2005-03-02 2011-08-23 Kodsi Robert E Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis
SI1698630T1 (sl) 2005-03-03 2015-01-30 Alfa Wassermann S.P.A. Nove polimorfne oblike rifaksimina, postopki za njihovo pripravo in njihova uporaba v medicinskih pripravkih
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
BRPI0714724A8 (pt) * 2006-08-02 2018-04-10 Salix Pharmaceuticals Inc métodos para tratar enterite, para proteger contra a enterite, contra a lesão à mucosa do cólon e contra a inflamação colorretal induzidas pela radiação, para tratar enterite em um indivíduo ou monitorar o progresso de um indivíduo que é tratado de enterite, para selecionar um indivíduo para o tratamento de enterite, e, para tratar diarréia profilaticamente.
US20080161337A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Chronic Prostatitis
US20080159987A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Restless Legs Syndrome
PT2327407E (pt) * 2008-09-26 2014-09-10 Aska Pharm Co Ltd Agentes profiláticos e/ou terapêuticos para desordens gastrointestinais funcionais
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
DK3628319T3 (da) 2008-10-02 2024-03-04 Salix Pharmaceuticals Ltd Behandling af hepatisk encefalopati ved anvendelse af rifaximin
WO2011061519A2 (en) 2009-11-23 2011-05-26 Cipla Limited Topical foam composition
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
WO2011110930A2 (en) * 2010-03-10 2011-09-15 Lupin Limited Rifaximin ready-to-use suspension
WO2012035283A1 (en) 2010-09-13 2012-03-22 Cipla Limited Pharmaceutical composition
WO2012076832A1 (en) 2010-12-09 2012-06-14 Cipla Limited Suppositories comprising rifaximin
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
ES2621557T3 (es) 2014-03-31 2017-07-04 Euticals S.P.A. Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas
PL3546464T3 (pl) 2014-05-12 2020-11-02 Alfasigma S.P.A. Sposób wytwarzania i zastosowanie postaci krystalicznej Tau rifaksyminy solwatowanej z DEGME
CN106999477B (zh) * 2014-06-30 2020-04-10 萨利克斯药品公司 用于重复治疗肠易激综合征(ibs)的方法
WO2016138118A1 (en) * 2015-02-26 2016-09-01 Jaguar Animal Health, Inc. Use of croton- or calophyllum-derived proanthocyanidin polymers or botanical extracts in combination with rifaximin for the treatment of diarrhea in non-human animals
CA2988930A1 (en) * 2015-06-10 2016-12-15 Synlogic, Inc. Bacteria engineered to treat diseases associated with hyperammonemia
WO2018069938A1 (en) 2016-10-14 2018-04-19 Cipla Limited Pharmaceutical compositions comprising rifaximin

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1264494B1 (it) * 1993-03-23 1996-09-24 Alfa Wassermann Spa Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter

Also Published As

Publication number Publication date
EP0858804A1 (en) 1998-08-19
DK0858804T3 (da) 2002-07-08
CN1115146C (zh) 2003-07-23
HUP9800115A1 (hu) 1999-06-28
HU224592B1 (hu) 2005-11-28
DE69805672T2 (de) 2003-01-23
HU9800115D0 (en) 1998-03-30
IT1290679B1 (it) 1998-12-10
JP4848083B2 (ja) 2011-12-28
KR100436243B1 (ko) 2004-08-25
ATE218342T1 (de) 2002-06-15
ES2178048T3 (es) 2002-12-16
PT858804E (pt) 2002-10-31
EP0858804B1 (en) 2002-06-05
CN1214244A (zh) 1999-04-21
JPH10226645A (ja) 1998-08-25
ITBO970064A1 (it) 1998-08-14
KR19980071348A (ko) 1998-10-26
DE69805672D1 (de) 2002-07-11
HUP9800115A3 (en) 2000-04-28
US5886002A (en) 1999-03-23

Similar Documents

Publication Publication Date Title
ITBO970064A0 (it) Uso della rifaximina e delle composizioni farmaceutiche che la conteng ono nel trattamento della diarrea da criptosporidiosi.
BR9607851B1 (pt) combinaÇço e formulaÇço farmacÊutica.
BR0211769A (pt) Combinações antineoplásicas
DE69729115D1 (de) Verbindungen mit analgetischer wirkung
CA2429020A1 (en) Use of cci-779 as an antineoplastic agent
BR9707501A (pt) Composto composição farmacêutica e uso do composto
IS5504A (is) Samsetning virk við meðhöndlun á getuleysi
BR9707812A (pt) Composto composto farmacêutica e uso do composto
SE9904377D0 (sv) Pharmaceutical combinations
DE69724629D1 (de) Zusammensetzungen und deren verwendungen
TR199800117A3 (tr) Isaksazol- ve krotonasitamid türevleri ve bunlarin kullanimi.
BR9707808A (pt) Composto composição farmacêutica e uso do composto
IT1282765B1 (it) Valvola di omogeneizzazione
DE69715701T2 (de) Photopolymerisierbare Zusammensetzung und gehärtete, transparente Gegenstände
BR9811958B1 (pt) uso de um absorvedor de uv derivado de bis(resorcinil)triazina e formulaÇço cosmÉtica compreendendo o mesmo.
BR9506389B1 (pt) composto de silìcio, e, composição dietética, cosmética e terapêutica.
NL1007839A1 (nl) Formulering en gebruik.
DE59706199D1 (de) Rückschlagventilanordnung
DE69717186D1 (de) Rückschlagventil
IT1292103B1 (it) Composizioni farmaceutiche topiche contenenti pirfenossone e uso dello stesso nel trattamento di condizioni infiammatorie
KR970059103U (ko) 첵크밸브
DE29613932U1 (de) Magenbitterrezeptur
DE69725034D1 (de) Diffusionspumpe
DE69723179D1 (de) Diffusionspumpe
IT1246344B (it) Metodo di dosaggio enzimoimmunologio e corredo di dosaggio relativo.

Legal Events

Date Code Title Description
0001 Granted